Stay updated on Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial page.

Latest updates to the Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial page
- Check4 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedRevision: v3.4.2 was added, and the prior notice about government funding lapse and NIH operating status was removed (associated with Revision: v3.4.1).SummaryDifference0.5%

- Check40 days agoChange DetectedBanner notice informs users about a lapse in government funding and that the NIH Clinical Center is open, with status updates available at opm.gov. Site revision updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check47 days agoChange DetectedAdministrative UI and metadata updates were made to the study page, including showing a glossary, updating QC-related labels to 'Last Update Submitted that Met QC Criteria', and adding a revision tag (v3.4.0). These changes do not affect the core study details or results, and the page's key information remains the same. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page shows a minor revision update (v3.3.4 added, v3.3.3 removed) that does not affect study details; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check82 days agoChange DetectedAdded a Locations section including Beijing Municipality and updated the page revision to v3.3.3. Removed the Beijing Municipality Locations subsection and the HHS Vulnerability Disclosure link.SummaryDifference0.2%

Stay in the know with updates to Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Surufatinib & JS001 Combo in Advanced Solid Tumors Clinical Trial page.